Lti share price

Aptose Biosciences Inc. is a Canada-based clinical stage precision oncology biotechnology company. It is engaged in advancing kinase inhibitors to treat unmet medical needs in life-threatening cancers, such as acute myeloid l eukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndrome (MDS) and other hematologic malignancies. Its HM43239 is being evaluated in an international Phase I/II study in patients with relapsed or refractory AML. Its Luxeptinib is being evaluated in a Phase I a/b trial in patients with relapsed or refractory B cell malignancies, and in a separate Phase I a/b trial in patients with relapsed or refractory AML or high-risk MDS. Its APTO-253 is a small molecule MYC oncogene inhibitor at the Phase Ia/b clinical trial stage of development for the treatment of patients with relapsed or refractory (R/R) blood cancers, including AML and high-risk MDS. Its APL-581 is a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suit...

Date Time Trade Prc Volume Buy/Sell Bid Ask Value 15-Jun-23 16:18:48 987.12 1 Unknown* 980.00 1,010.00 987.12 O Ordinary 15-Jun-23 16:14:51 988.01 2 Unknown* 980.00 1,010.00 1,976 O Ordinary 15-Jun-23 16:11:46 989.00 2 Unknown* 980.00 1,010.00 1,978 O Ordinary 15-Jun-23 15:55:40 973.14 10 Sell* 980.00 1,010.00 9,731 O Ordinary Non protected portfolio Single protected transaction 15-Jun-23 15:39:35 994.062 10 Unknown* 980.00 1,010.00 9,941 O Ordinary 15-Jun-23 15:16:41 995.768 1 Buy* 980.00 1,010.00 995.77 O Ordinary 15-Jun-23 15:10:12 996.401 1 Buy* 980.00 1,010.00 996.40 O Ordinary 15-Jun-23 15:00:03 997.034 1 Buy* 980.00 1,010.00 997.03 O Ordinary 15-Jun-23 14:50:05 1,010.00 1 Buy* 980.00 1,010.00 1,010 A Automatic Execution 15-Jun-23 14:47:22 1,000.6115 1 Buy* 980.00 1,015.00 1,001 O Ordinary Announced Traded Action Notifier Price Currency Amount Holding 19-Apr-23 19-Apr-23 Buy Helena Vinnicombe held the position of Independent Non-Executive Director at the time of this trade.Helena Vinnicombe 104,200.00 GBX 8 23 17-Apr-23 17-Apr-23 Buy Michael Lindsell held the position of Independent Non-Executive Director at the time of this trade.Michael Lindsell 104,600.00 GBX 25 8,142 14-Apr-23 14-Apr-23 Buy Michael Lindsell held the position of Independent Non-Executive Director at the time of this trade.Michael Lindsell 104,300.00 GBX 25 8,117 14-Apr-23 14-Apr-23 Buy Michael Lindsell held the position of Independent Non-Executive Director at the time of this trade.Michael Lindse...

LTIMindtree Limited is an India-based global technology consulting and digital solutions company. The Company is engaged in the business of analyzing, designing, maintaining, converting, porting, debugging, coding, outsourcing and programming software and also providing information technology enabled services. The Company operates through five segments: Banking, Financial Services & Insurance; High-Tech, Media & Entertainment; Manufacturing & Resources; Retail, CPG & Travel, Transport & Hospitality; and Health & Public Services. Its services include cloud and infrastructure training, consulting, customer success, cyber security, data and insights, digital engineering, Disruptive software-as-a-service (D-SaaS), platform operations, intelligent automation solutions, and assurance and quality engineering. Its platforms include LTI Infinity, Fosfor, LTI Canvas, Mindtree NxT, Unitrax, REDaxis, and Advanced Smart City Operating Platform.;